<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01220726</url>
  </required_header>
  <id_info>
    <org_study_id>BTX0621</org_study_id>
    <nct_id>NCT01220726</nct_id>
  </id_info>
  <brief_title>Botox for the Treatment of Overactive Bladder Secondary to Benign Prostatic Obstruction</brief_title>
  <official_title>Randomized Double-blind Placebo Controlled Trial of Intradetrusor Injections of Botox for the Treatment of Refractory Overactive Bladder Secondary to Benign Prostatic Obstruction-BTX0621</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, double-blind study comparing intravesical injection of
      BOTOX to placebo. Study subjects will be randomized (1:1 ratio) to one of the following
      treatment groups:
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Group 1 n=20 BOTOX® 200U Group 2 n=20 Placebo BOTOX® (saline) At Visit 2 (Treatment, Day 0),
      subjects will receive one injection cycle of BOTOX (200U) or placebo (saline). The study
      duration is approximately 284 days and consists of a Screening Visit (Day -7 to -14), a
      Treatment/Randomization Visit (Visit 2, Day 0), and Follow-up Visits at 7, 30, 90, 180, and
      270 Days. Telephone Follow-ups will be made 3 days following the injection cycle.

      Subjects demonstrating an insufficient response to treatment may receive an open-label
      injection cycle of BOTOX (200U) at Day 90. Subjects receiving this injection will re-commence
      Follow-up Visits and be followed for an additional 270 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">November 13, 2012</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary Frequency</measure>
    <time_frame>From Baseline to Day 270</time_frame>
    <description>This is the measure of urinary frequency at baseline for those in the placebo and botox arms to day 270</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urgency</measure>
    <time_frame>From Baseline to Day 270</time_frame>
    <description>This measured the degree of urinary urgency using a 3-day voiding diary. Patients were assessed for the number of urgency episodes they had by answering yes or no.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of Life (QoL)</measure>
    <time_frame>From Baseline to Day 270</time_frame>
    <description>Quality of Life (QoL) is from the ICIQ-QAB (international Consultation of Incontinence Overactive Bladder) Questionnaire. It is scored 25-160 and those with higher scores have higher impact on quality of life.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>International Consultation on Incontinence Questionnaire (ICIQ)</measure>
    <time_frame>From Baseline to Day 270</time_frame>
    <description>ICIQ is a brief validated instrument that is comprehensive for the assessment of incontinence and measures frequency, severity and impact on quality of life. There are a total of 23 items. The overall score ranges from 1-84 with greater values indicating increased symptom severity. Bother scales are not incorporated in the overall score but indicate impact of individual symptoms for the patient.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postvoid Residual Volume (PVR)</measure>
    <time_frame>From Baseline to Day 270</time_frame>
    <description>Postvoid residual volume (PVR) is the volume of fluid remaining in the bladder immediately after the completion of micturition.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Flow Rate (Qmax)</measure>
    <time_frame>From Baseline to Day 270</time_frame>
    <description>Qmax is the the maximum recorded flow rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>International Prostate Symptom Score (IPSS)</measure>
    <time_frame>From Baseline to Day 270</time_frame>
    <description>International Prostate Symptom Score (IPSS) -is a 7 point scale used to screen, track and manage symptoms associated with BPH. The symptoms questions include feeling of incomplete bladder emptying, frequency, intermittency, urgency, weak stream, straining and nocturia. Scores range from 1 to 5 for a total of maximum 35 points (0-7 Mildly symptomatic, 8-19 Moderately symptomatic, 20-35 Severely symptomatic)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>Botox</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>200U onabotulinumtoxinA (botox)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>200U Saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botox</intervention_name>
    <description>Botox injection</description>
    <arm_group_label>Botox</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male outpatients of any race, between 40 and 90 years of age.

          2. Clinical signs and symptoms of frequency (&gt;=8 micturitions/day) and urgency (&gt;=2
             episodes/day).

          3. Urodynamic history consistent with OAB that developed in conjunction with BPO and that
             persists for at least 3 months post TURP or PVP, RRP or other obstruction relieving
             procedure.

          4. OAB inadequately controlled with anticholinergic medications, as per Investigator
             opinion.

          5. Qmax &gt;12mL/s with a voided volume of &gt;125mL.

          6. IPSS &gt;12, with IPSS QoL &gt;3 at study Visit 1.

          7. Willing to use clean intermittent catheterization (CIC) to empty the bladder or is
             willing to have an indwelling catheter, if necessary following study treatment.

          8. Able to understand the requirements of the study, including completing questionnaires
             and signing Informed Consent/HIPAA.

        Exclusion Criteria:

          1. Known history of interstitial cystitis, uninvestigated hematuria, bladder outlet
             obstruction due to vesical neck contracture, mullerian duct cysts, urethral
             obstruction due to stricture/valves/sclerosis of urethral tumor, radiation cystitis,
             genitourinary tuberculosis, bladder calculi, or detrusor-sphincter dyssynergia.

          2. Known history of clinically significant cardiovascular disease, cerebrovascular
             disease, or arrhythmia.

          3. History of spinal cord injury or multiple sclerosis, or other neurological disease
             which may be contributing to OAB.

          4. Known history of hydronephrosis.

          5. Current indwelling catheter, or removal of chronic catheter &lt;1 month prior to study
             entry.

          6. Non-compliance with wash-out periods for prohibited medications/therapies (Supplement
             I).

          7. Evidence of Urinary Tract Infection according to local standard of care.

          8. Serum PSA of &gt;10ng/mL.

          9. 24 hour total volume voided &gt;3000 mL of urine. [As determined by completion of a
             patient bladder diary during the screening period]

         10. Medical condition that may increase their risk of exposure to botulinum toxin
             including diagnosed Myasthenia Gravis, Eaton-Lambert Syndrome, Amyotrophic Lateral
             Sclerosis or any other disease that might interfere with neuromuscular function.

         11. Allergy or sensitivity to any component of BOTOX® (Section 5.2).

         12. Known uncontrolled systemic disease.

         13. Evidence of recent alcohol/drug abuse.

         14. Subjects who, in the opinion of the Investigator, have a significant condition that
             puts them at significant risk, may confound study results, or interfere with study
             participation.

         15. History of poor cooperation, non-compliance with medical treatment, or unreliability.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexis Te</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>June 22, 2010</study_first_submitted>
  <study_first_submitted_qc>October 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2010</study_first_posted>
  <results_first_submitted>March 22, 2017</results_first_submitted>
  <results_first_submitted_qc>February 7, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 26, 2019</results_first_posted>
  <last_update_submitted>February 7, 2019</last_update_submitted>
  <last_update_submitted_qc>February 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>OAB</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The total number of participants recruited and enrolled was 30. A total of 28 completed the study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Botox</title>
          <description>200U onabotulinumtoxinA (botox)
Botox: Botox injection</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>200U Saline
Placebo: Placebo injection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Botox</title>
          <description>200U onabotulinumtoxinA (botox)
Botox: Botox injection</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>200U Saline
Placebo: Placebo injection</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80" lower_limit="48" upper_limit="87"/>
                    <measurement group_id="B2" value="68" lower_limit="53" upper_limit="83"/>
                    <measurement group_id="B3" value="74" lower_limit="48" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.7" lower_limit="20" upper_limit="30.4"/>
                    <measurement group_id="B2" value="32.5" lower_limit="24" upper_limit="38"/>
                    <measurement group_id="B3" value="28" lower_limit="20" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline International Prostate Symptom Score</title>
          <description>International Prostate Symptom Score (IPSS) is a 7 point scale used to screen, track and manage symptoms associated with BPH. The symptoms questions include feeling of incomplete bladder emptying, frequency, intermittency, urgency, weak stream, straining and nocturia. Scores range from 1 to 5 for a total of maximum 35 points (0-7 Mildly symptomatic, 8-19 Moderately symptomatic, 20-35 Severely symptomatic).</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16" lower_limit="13" upper_limit="23"/>
                    <measurement group_id="B2" value="20" lower_limit="12" upper_limit="23"/>
                    <measurement group_id="B3" value="18" lower_limit="12.5" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline maximum flow rate (Qmax)</title>
          <description>Maximum flow rate (Qmax) is the the maximum recorded flow rate</description>
          <units>mL/s</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.1" spread="10.5"/>
                    <measurement group_id="B2" value="16.0" spread="5.8"/>
                    <measurement group_id="B3" value="18.6" spread="8.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Voided Volume</title>
          <description>Voided volume is the amount of urine output during a micturition.</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="265.4" spread="132.3"/>
                    <measurement group_id="B2" value="212.6" spread="74.5"/>
                    <measurement group_id="B3" value="239" spread="103.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline postvoid residual volume (PVR)</title>
          <description>Postvoid residual volume (PVR) is the volume of fluid remaining in the bladder immediately after the completion of micturition.</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.3" spread="39.5"/>
                    <measurement group_id="B2" value="34.8" spread="31.2"/>
                    <measurement group_id="B3" value="36.55" spread="35.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Voiding frequency</title>
          <description>This is the frequency of micturitions during a 24-hour period.</description>
          <units>times voided</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11" lower_limit="9" upper_limit="14"/>
                    <measurement group_id="B2" value="10.5" lower_limit="8" upper_limit="13"/>
                    <measurement group_id="B3" value="10.75" lower_limit="9" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type of Procedure: TURP or Laser</title>
          <description>Transurethral resection of the prostate (TURP) involves resecting the prostatic tissue, while a laser procedure involves vaporizing the tissue using a laser.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>TURP</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Laser</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Urinary Frequency</title>
        <description>This is the measure of urinary frequency at baseline for those in the placebo and botox arms to day 270</description>
        <time_frame>From Baseline to Day 270</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>200U Saline
Placebo: Placebo injection</description>
          </group>
          <group group_id="O2">
            <title>Botox</title>
            <description>200U onabotulinumtoxinA (botox)
Botox: Botox injection</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Frequency</title>
          <description>This is the measure of urinary frequency at baseline for those in the placebo and botox arms to day 270</description>
          <units>urinations</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" lower_limit="8" upper_limit="13"/>
                    <measurement group_id="O2" value="11" lower_limit="9" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="9" upper_limit="14"/>
                    <measurement group_id="O2" value="8.5" lower_limit="7" upper_limit="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="8" upper_limit="13"/>
                    <measurement group_id="O2" value="8" lower_limit="7" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="7" upper_limit="13"/>
                    <measurement group_id="O2" value="8" lower_limit="7" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="8" upper_limit="14"/>
                    <measurement group_id="O2" value="9" lower_limit="8" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 270</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" lower_limit="5" upper_limit="10"/>
                    <measurement group_id="O2" value="9.5" lower_limit="7" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urgency</title>
        <description>This measured the degree of urinary urgency using a 3-day voiding diary. Patients were assessed for the number of urgency episodes they had by answering yes or no.</description>
        <time_frame>From Baseline to Day 270</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>200U Saline
Placebo: Placebo injection</description>
          </group>
          <group group_id="O2">
            <title>Botox</title>
            <description>200U onabotulinumtoxinA (botox)
Botox: Botox injection</description>
          </group>
        </group_list>
        <measure>
          <title>Urgency</title>
          <description>This measured the degree of urinary urgency using a 3-day voiding diary. Patients were assessed for the number of urgency episodes they had by answering yes or no.</description>
          <units>episodes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="1" upper_limit="10"/>
                    <measurement group_id="O2" value="2" lower_limit="2" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="1.5" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 270</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Quality of Life (QoL)</title>
        <description>Quality of Life (QoL) is from the ICIQ-QAB (international Consultation of Incontinence Overactive Bladder) Questionnaire. It is scored 25-160 and those with higher scores have higher impact on quality of life.</description>
        <time_frame>From Baseline to Day 270</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>200U Saline
Placebo: Placebo injection</description>
          </group>
          <group group_id="O2">
            <title>Botox</title>
            <description>200U onabotulinumtoxinA (botox)
Botox: Botox injection</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life (QoL)</title>
          <description>Quality of Life (QoL) is from the ICIQ-QAB (international Consultation of Incontinence Overactive Bladder) Questionnaire. It is scored 25-160 and those with higher scores have higher impact on quality of life.</description>
          <units>scores on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="79" upper_limit="93"/>
                    <measurement group_id="O2" value="73" lower_limit="60" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.5" lower_limit="82.5" upper_limit="100.5"/>
                    <measurement group_id="O2" value="81.5" lower_limit="47" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="90" upper_limit="94"/>
                    <measurement group_id="O2" value="82.5" lower_limit="63" upper_limit="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91" lower_limit="66" upper_limit="103"/>
                    <measurement group_id="O2" value="88" lower_limit="61" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.5" lower_limit="88.5" upper_limit="105.5"/>
                    <measurement group_id="O2" value="79" lower_limit="59" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 270</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="93" upper_limit="107"/>
                    <measurement group_id="O2" value="79" lower_limit="67" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>International Consultation on Incontinence Questionnaire (ICIQ)</title>
        <description>ICIQ is a brief validated instrument that is comprehensive for the assessment of incontinence and measures frequency, severity and impact on quality of life. There are a total of 23 items. The overall score ranges from 1-84 with greater values indicating increased symptom severity. Bother scales are not incorporated in the overall score but indicate impact of individual symptoms for the patient.</description>
        <time_frame>From Baseline to Day 270</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>200U Saline
Placebo: Placebo injection</description>
          </group>
          <group group_id="O2">
            <title>Botox</title>
            <description>200U onabotulinumtoxinA (botox)
Botox: Botox injection</description>
          </group>
        </group_list>
        <measure>
          <title>International Consultation on Incontinence Questionnaire (ICIQ)</title>
          <description>ICIQ is a brief validated instrument that is comprehensive for the assessment of incontinence and measures frequency, severity and impact on quality of life. There are a total of 23 items. The overall score ranges from 1-84 with greater values indicating increased symptom severity. Bother scales are not incorporated in the overall score but indicate impact of individual symptoms for the patient.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="5" upper_limit="12"/>
                    <measurement group_id="O2" value="9" lower_limit="4" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="3" upper_limit="7"/>
                    <measurement group_id="O2" value="8" lower_limit="5" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="1" upper_limit="8"/>
                    <measurement group_id="O2" value="7" lower_limit="5" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Insufficient number of participants with this event.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Insufficient number of participants with this event.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="1" upper_limit="6"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 270</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="3" upper_limit="4"/>
                    <measurement group_id="O2" value="8.5" lower_limit="6" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Postvoid Residual Volume (PVR)</title>
        <description>Postvoid residual volume (PVR) is the volume of fluid remaining in the bladder immediately after the completion of micturition.</description>
        <time_frame>From Baseline to Day 270</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>200U Saline
Placebo: Placebo injection</description>
          </group>
          <group group_id="O2">
            <title>Botox</title>
            <description>200U onabotulinumtoxinA (botox)
Botox: Botox injection</description>
          </group>
        </group_list>
        <measure>
          <title>Postvoid Residual Volume (PVR)</title>
          <description>Postvoid residual volume (PVR) is the volume of fluid remaining in the bladder immediately after the completion of micturition.</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.8" spread="31.2"/>
                    <measurement group_id="O2" value="36" spread="39.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.7" spread="NA">After extensive research and review of files, standard deviation cannot be located.</measurement>
                    <measurement group_id="O2" value="137.1" spread="NA">After extensive research and review of files, standard deviation cannot be located.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.3" spread="NA">After extensive research and review of files, standard deviation cannot be located.</measurement>
                    <measurement group_id="O2" value="73.1" spread="NA">After extensive research and review of files, standard deviation cannot be located.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Insufficient number of participants with this event.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Insufficient number of participants with this event.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151.6" spread="NA">After extensive research and review of files, standard deviation cannot be located.</measurement>
                    <measurement group_id="O2" value="168.6" spread="NA">After extensive research and review of files, standard deviation cannot be located.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 270</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.2" spread="NA">After extensive research and review of files, standard deviation cannot be located.</measurement>
                    <measurement group_id="O2" value="54.4" spread="NA">After extensive research and review of files, standard deviation cannot be located.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Flow Rate (Qmax)</title>
        <description>Qmax is the the maximum recorded flow rate</description>
        <time_frame>From Baseline to Day 270</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>200U Saline
Placebo: Placebo injection</description>
          </group>
          <group group_id="O2">
            <title>Botox</title>
            <description>200U onabotulinumtoxinA (botox)
Botox: Botox injection</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Flow Rate (Qmax)</title>
          <description>Qmax is the the maximum recorded flow rate</description>
          <units>mL/s</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" spread="5.8"/>
                    <measurement group_id="O2" value="21.1" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" spread="NA">After extensive research and review of files, standard deviation cannot be located.</measurement>
                    <measurement group_id="O2" value="15.7" spread="NA">After extensive research and review of files, standard deviation cannot be located.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" spread="NA">After extensive research and review of files, standard deviation cannot be located.</measurement>
                    <measurement group_id="O2" value="16.5" spread="NA">After extensive research and review of files, standard deviation cannot be located.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9" spread="NA">After extensive research and review of files, standard deviation cannot be located.</measurement>
                    <measurement group_id="O2" value="10.3" spread="NA">After extensive research and review of files, standard deviation cannot be located.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" spread="NA">After extensive research and review of files, standard deviation cannot be located.</measurement>
                    <measurement group_id="O2" value="12.8" spread="NA">After extensive research and review of files, standard deviation cannot be located.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 270</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" spread="NA">After extensive research and review of files, standard deviation cannot be located.</measurement>
                    <measurement group_id="O2" value="12.9" spread="NA">After extensive research and review of files, standard deviation cannot be located.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>International Prostate Symptom Score (IPSS)</title>
        <description>International Prostate Symptom Score (IPSS) -is a 7 point scale used to screen, track and manage symptoms associated with BPH. The symptoms questions include feeling of incomplete bladder emptying, frequency, intermittency, urgency, weak stream, straining and nocturia. Scores range from 1 to 5 for a total of maximum 35 points (0-7 Mildly symptomatic, 8-19 Moderately symptomatic, 20-35 Severely symptomatic)</description>
        <time_frame>From Baseline to Day 270</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>200U Saline
Placebo: Placebo injection</description>
          </group>
          <group group_id="O2">
            <title>Botox</title>
            <description>200U onabotulinumtoxinA (botox)
Botox: Botox injection</description>
          </group>
        </group_list>
        <measure>
          <title>International Prostate Symptom Score (IPSS)</title>
          <description>International Prostate Symptom Score (IPSS) -is a 7 point scale used to screen, track and manage symptoms associated with BPH. The symptoms questions include feeling of incomplete bladder emptying, frequency, intermittency, urgency, weak stream, straining and nocturia. Scores range from 1 to 5 for a total of maximum 35 points (0-7 Mildly symptomatic, 8-19 Moderately symptomatic, 20-35 Severely symptomatic)</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="12" upper_limit="23"/>
                    <measurement group_id="O2" value="16" lower_limit="13" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5" lower_limit="8" upper_limit="20"/>
                    <measurement group_id="O2" value="15.5" lower_limit="13" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="11" upper_limit="18"/>
                    <measurement group_id="O2" value="15" lower_limit="8" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="10" upper_limit="24"/>
                    <measurement group_id="O2" value="10" lower_limit="5" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 180</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" lower_limit="11" upper_limit="19.5"/>
                    <measurement group_id="O2" value="17" lower_limit="13" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 270</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="10" upper_limit="18"/>
                    <measurement group_id="O2" value="15" lower_limit="12" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events were collected over 1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Botox</title>
          <description>Number of adverse events that occurred in the botox arm</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Number of adverse events that occurred in the placebo arm</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Acute Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Alexis Te</name_or_title>
      <organization>Weill Cornell Medical College</organization>
      <phone>646-962-4811</phone>
      <email>aet2005@med.cornell.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

